Healthcare · Biotechnology
Price
$22.90
Market Cap
$2.0B
Employees
314
Beta
1.87
Avg Volume
1,782,924
CEO
Arthur T. Sands
Business Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-7.51
Stock Price: $22.90
EPS (Diluted): -3.05
EPS (Diluted): -3.05
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.72
Stock Price: $22.90
Total Equity: $538.75M
Shares: 86,666,907
Total Equity: $538.75M
Shares: 86,666,907
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-7.19
Market Cap: $1.98B
Total Debt: $0.00
Cash: $246.96M
EBITDA: -$244.84M
Total Debt: $0.00
Cash: $246.96M
EBITDA: -$244.84M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.3B
Market Cap: $1.98B
Total Debt: $0.00
Cash: $246.96M
Total Debt: $0.00
Cash: $246.96M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
17.45
Stock Price: $22.90
Revenue: $83.98M
Shares: 86,666,907
Revenue: $83.98M
Shares: 86,666,907
EV/Sales (Total value vs revenue — works when P/E can't)
API15.17
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
77.5%
Gross Profit: $65.12M
Revenue: $83.98M
Revenue: $83.98M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-340.2%
Operating Income: -$285.67M
Revenue: $83.98M
Revenue: $83.98M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-314.9%
Net Income: -$264.46M
Revenue: $83.98M
Revenue: $83.98M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-64.2%
Net Income: -$264.46M
Total Equity: $538.75M
Total Equity: $538.75M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-57.6%
Operating Income: -$285.67M
Tax Rate: -0.3%
Equity: $538.75M
Total Debt: $0.00
Cash: $246.96M
Tax Rate: -0.3%
Equity: $538.75M
Total Debt: $0.00
Cash: $246.96M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
7.02
Current Assets: $606.82M
Current Liabilities: $86.47M
Current Liabilities: $86.47M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $538.75M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $538.75M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.97
Revenue: $83.98M
Shares: 86,666,907
Shares: 86,666,907
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$6.22
Total Equity: $538.75M
Shares: 86,666,907
Shares: 86,666,907
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.04
Operating CF: -$249.47M
CapEx: -$14.00M
Shares: 86,666,907
CapEx: -$14.00M
Shares: 86,666,907
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $22.90
Stock Price: $22.90
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$264.46M
Net Income: -$264.46M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares NRIX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:39pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Cost of Revenue | $116.4M | $184.5M | $189.1M | $221.6M | $18.9M |
| Gross Profit | -$86.7M | -$145.9M | -$112.2M | -$167.1M | $65.1M |
| Operating Expenses | $31.2M | $38.0M | $42.9M | $45.9M | $350.8M |
| Operating Income | -$117.9M | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| Net Income | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| EBITDA | -$115.1M | -$176.2M | -$137.8M | -$185.3M | -$244.8M |
| EPS | $-2.73 | $-3.71 | $-2.65 | $-2.88 | $-3.05 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:39pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $80.5M | $64.5M | $54.6M | $110.0M | $247.0M |
| Total Current Assets | $311.1M | $318.4M | $295.5M | $619.4M | $606.8M |
| Total Assets | $476.8M | $416.8M | $355.6M | $669.3M | $688.1M |
| Current Liabilities | $66.3M | $70.7M | $87.0M | $95.9M | $86.5M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $134.5M | $113.1M | $155.1M | $142.4M | $149.4M |
| Total Equity | $342.3M | $303.7M | $200.5M | $527.0M | $538.7M |
| Retained Earnings | -$220.9M | -$401.3M | -$545.2M | -$738.8M | -$1.0B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:39pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$84.4M | -$159.8M | -$81.4M | -$172.6M | -$249.5M |
| Capital Expenditure | -$5.7M | -$12.2M | -$8.4M | -$9.3M | -$14.0M |
| Free Cash Flow | -$90.0M | -$172.1M | -$89.8M | -$181.9M | -$263.5M |
| Acquisitions (net) | $102.6M | -$39.4M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$38.7M | -$15.4M | -$9.8M | $55.4M | $137.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 4:33am (4h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$81.6M $36.1M – $173.7M
|
$180.3M $180.3M – $180.3M
|
$251.9M $83.9M – $881.2M
|
$426.4M $142.0M – $1.5B
|
| EBITDA |
-$81.6M -$173.7M – -$36.1M
|
-$180.3M -$180.3M – -$180.3M
|
-$251.9M -$881.2M – -$83.9M
|
-$426.4M -$1.5B – -$142.0M
|
| Net Income |
-$213.6M -$271.6M – -$155.6M
|
-$201.1M -$301.6M – $279.0M
|
-$126.6M -$537.9M – -$16.8M
|
-$41.4M -$175.8M – -$5.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:39pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +29.8% | +99.3% | -29.1% | +54.0% |
| Gross Profit Growth | -68.3% | +23.1% | -49.0% | +139.0% |
| Operating Income Growth | -56.0% | +15.7% | -37.4% | -34.1% |
| Net Income Growth | -53.9% | +20.2% | -34.5% | -36.6% |
| EBITDA Growth | -53.1% | +21.8% | -34.4% | -32.1% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:33am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-25 | Hansen Gwenn | S-Sale | 5,394.00 | $20.00 | $107,880 |
| 2026-06-25 | Ring Christine | M-Exempt | 15,602.00 | $8.72 | $136,049 |
| 2026-06-25 | Ring Christine | M-Exempt | 15,602.00 | $8.72 | $136,049 |
| 2026-06-25 | Ring Christine | M-Exempt | 13,333.00 | $7.26 | $96,798 |
| 2026-06-25 | Ring Christine | S-Sale | 28,935.00 | $20.06 | $580,506 |
| 2026-06-25 | Ring Christine | M-Exempt | 13,333.00 | $7.26 | $96,798 |
| 2026-06-02 | Ring Christine | M-Exempt | 3,422.00 | $1.86 | $6,365 |
| 2026-06-02 | Ring Christine | S-Sale | 8,148.00 | $16.60 | $135,253 |
| 2026-06-02 | Ring Christine | M-Exempt | 3,422.00 | $1.86 | $6,365 |
| 2026-05-15 | Silva Paul M | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | Saltzman Edward C | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | Reinsdorf Judith A | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | Lacey David L. | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | Kapur Anil | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | DANSEY ROGER D | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | Baynes Roy D. | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-15 | GREGORY JULIA P | A-Award | 31,250.00 | $15.86 | $495,625 |
| 2026-05-05 | van Houte Hans | S-Sale | 13,473.00 | $16.58 | $223,323 |
| 2026-05-05 | van Houte Hans | S-Sale | 582.00 | $17.18 | $9,996 |
| 2026-05-04 | Ring Christine | S-Sale | 8,148.00 | $16.96 | $138,210 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for NRIX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for NRIX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30